- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02464150
Gluten Challenge in Celiac Disease
June 17, 2025 updated by: Knut E. A. Lundin, Oslo University Hospital
Up till 30 participants with celiac disease on a glutenfree diet are asked to consume gluten containing cookies or bread for 3 days.
Questionnaires and sampling of blood is done before, during and after.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Before and 6 days after start of gluten challenge, blood samples will be collected and analysed by using HLA-tetramers to identify and purify CD4+ gluten-specific T cells by flow cytometry.
T cells will undergo transcriptome analysis to get an insight in signalling of antigen-specific cells.
Other cell populations like CD8+ T cells and γδ T cells will also be analyzed by flow cytometry.
Study Type
Interventional
Enrollment (Actual)
99
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Oslo, Norway, 0372
- Oslo University Hospital - Rikshospitalet
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Celiac disease confirmed by biopsy
- Age 18 - 80 years
- Gluten free diet last 6 months
- Subject has received information and signed the informed consent form
Exclusion Criteria:
- Pregnant or breast feeding
- Probability of participant becoming pregnant (f.ex. by not using adequate sexual prevention by woman in fertile age)
- Drugs influencing immune system used last 3 months
- Current infectious disease of moderate or high severity
- Other chronic active intestinal disease
- Serious reaction on small amounts of gluten ingested
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Participants
Participants are subjected to gluten intervention in an unblinded fashion.
|
Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Transcriptome of gluten-specific T cells
Time Frame: Day 6
|
Transcriptional differences of glutenspecific vs. unspecific T cells
|
Day 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Knut EA Lundin, MD PhD, Oslo University hospital and University of Oslo
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Skodje GI, Sarna VK, Minelle IH, Rolfsen KL, Muir JG, Gibson PR, Veierod MB, Henriksen C, Lundin KEA. Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity. Gastroenterology. 2018 Feb;154(3):529-539.e2. doi: 10.1053/j.gastro.2017.10.040. Epub 2017 Nov 2.
- Eggesbo LM, Risnes LF, Neumann RS, Lundin KEA, Christophersen A, Sollid LM. Single-cell TCR sequencing of gut intraepithelial gammadelta T cells reveals a vast and diverse repertoire in celiac disease. Mucosal Immunol. 2020 Mar;13(2):313-321. doi: 10.1038/s41385-019-0222-9. Epub 2019 Nov 14.
- Zuhlke S, Risnes LF, Dahal-Koirala S, Christophersen A, Sollid LM, Lundin KE. CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease. United European Gastroenterol J. 2019 Dec;7(10):1337-1344. doi: 10.1177/2050640619874183. Epub 2019 Sep 7.
- Risnes LF, Eggesbo LM, Zuhlke S, Dahal-Koirala S, Neumann RS, Lundin KEA, Christophersen A, Sollid LM. Circulating CD103+ gammadelta and CD8+ T cells are clonally shared with tissue-resident intraepithelial lymphocytes in celiac disease. Mucosal Immunol. 2021 Jul;14(4):842-851. doi: 10.1038/s41385-021-00385-8. Epub 2021 Mar 2.
- Dahal-Koirala S, Risnes LF, Neumann RS, Christophersen A, Lundin KEA, Sandve GK, Qiao SW, Sollid LM. Comprehensive Analysis of CDR3 Sequences in Gluten-Specific T-Cell Receptors Reveals a Dominant R-Motif and Several New Minor Motifs. Front Immunol. 2021 Apr 13;12:639672. doi: 10.3389/fimmu.2021.639672. eCollection 2021.
- Christophersen A, Zuhlke S, Lund EG, Snir O, Dahal-Koirala S, Risnes LF, Jahnsen J, Lundin KEA, Sollid LM. Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies. Adv Sci (Weinh). 2021 Nov;8(21):e2102778. doi: 10.1002/advs.202102778. Epub 2021 Sep 8.
- Christophersen A, Zuhlke S, Lund EG, Snir O, Dahal-Koirala S, Risnes LF, Jahnsen J, Lundin KEA, Sollid LM. Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies. Adv Sci (Weinh). 2022 Dec;9(34):e2205912. doi: 10.1002/advs.202205912. No abstract available.
- Stamnaes J, Stray D, Stensland M, Sarna VK, Nyman TA, Lundin KEA, Sollid LM. In Well-Treated Celiac Patients Low-Level Mucosal Inflammation Predicts Response to 14-day Gluten Challenge. Adv Sci (Weinh). 2021 Jan 4;8(4):2003526. doi: 10.1002/advs.202003526. eCollection 2021 Feb.
- Tye-Din JA, Skodje GI, Sarna VK, Dzuris JL, Russell AK, Goel G, Wang S, Goldstein KE, Williams LJ, Sollid LM, Lundin KE, Anderson RP. Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity. United European Gastroenterol J. 2020 Feb;8(1):108-118. doi: 10.1177/2050640619874173. Epub 2019 Sep 3.
- Goel G, Tye-Din JA, Qiao SW, Russell AK, Mayassi T, Ciszewski C, Sarna VK, Wang S, Goldstein KE, Dzuris JL, Williams LJ, Xavier RJ, Lundin KEA, Jabri B, Sollid LM, Anderson RP. Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Sci Adv. 2019 Aug 7;5(8):eaaw7756. doi: 10.1126/sciadv.aaw7756. eCollection 2019 Aug.
- Risnes LF, Christophersen A, Dahal-Koirala S, Neumann RS, Sandve GK, Sarna VK, Lundin KE, Qiao SW, Sollid LM. Disease-driving CD4+ T cell clonotypes persist for decades in celiac disease. J Clin Invest. 2018 Jun 1;128(6):2642-2650. doi: 10.1172/JCI98819. Epub 2018 May 14.
- Dahal-Koirala S, Risnes LF, Christophersen A, Sarna VK, Lundin KE, Sollid LM, Qiao SW. TCR sequencing of single cells reactive to DQ2.5-glia-alpha2 and DQ2.5-glia-omega2 reveals clonal expansion and epitope-specific V-gene usage. Mucosal Immunol. 2016 May;9(3):587-96. doi: 10.1038/mi.2015.147. Epub 2016 Feb 3.
- Sarna VK, Skodje GI, Reims HM, Risnes LF, Dahal-Koirala S, Sollid LM, Lundin KEA. HLA-DQ:gluten tetramer test in blood gives better detection of coeliac patients than biopsy after 14-day gluten challenge. Gut. 2018 Sep;67(9):1606-1613. doi: 10.1136/gutjnl-2017-314461. Epub 2017 Aug 4.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2017
Primary Completion (Actual)
May 13, 2025
Study Completion (Actual)
May 13, 2025
Study Registration Dates
First Submitted
March 30, 2015
First Submitted That Met QC Criteria
June 4, 2015
First Posted (Estimated)
June 8, 2015
Study Record Updates
Last Update Posted (Actual)
June 22, 2025
Last Update Submitted That Met QC Criteria
June 17, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013/1237
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Celiac Disease
-
Inonu UniversityNot yet recruitingCeliac Disease in Children | Celiac Disease in AdolescentsTurkey (Türkiye)
-
Tampere University HospitalTampere UniversityRecruitingCeliac Disease | Small Bowel Disease | Refractory Celiac DiseaseFinland
-
Boston Children's HospitalNot yet recruiting
-
Medical University of WarsawNot yet recruitingCoeliac Disease | Celiac Disease in Children
-
Medical University of WarsawNot yet recruitingCeliac Disease in Children | Gluten-free Diet
-
Ankara Yildirim Beyazıt UniversityRecruitingCeliac Disease | Adults With Celiac DiseaseTurkey (Türkiye)
-
University of OxfordCompletedCeliac Disease | Mental Health Wellness 1 | Emotional Problem | Stigma, Social | Celiac Disease in Children | Celiac | DisclosureUnited Kingdom
-
IRCCS Burlo GarofoloRecruitingCeliac Disease in ChildrenItaly
-
Cairo UniversityNot yet recruitingCeliac Disease in Children
-
Meir Medical CenterTerminatedCeliac Disease in ChildrenIsrael
Clinical Trials on Gluten challenge
-
Hospital Mutua de TerrassaCompletedCeliac Disease | Non-celiac Gluten Sensitivity
-
Medical University of WarsawNutricia FoundationUnknown
-
AmgenCompletedCeliac DiseaseFinland
-
Joslin Diabetes CenterImmusanT, Inc.CompletedType 1 Diabetes | Celiac DiseaseUnited States
-
Oslo University HospitalUniversity of Oslo; South-Eastern Norway Regional Health AuthorityCompleted
-
James Cook University, Queensland, AustraliaNational Health and Medical Research Council, Australia; The Prince Charles... and other collaboratorsCompleted
-
University of PalermoCompleted
-
Massachusetts General HospitalTerminated
-
Göteborg UniversitySahlgrenska University Hospital, Sweden; University of Skövde; Ekhaga foundationRecruitingDiabetes | Celiac Disease | Metabolic Disease | AutoimmunitySweden
-
Università degli Studi di BresciaUnknownNon Celiac Gluten SensitivityItaly